Effect of therapeutic regimens and polypharmacy on health-related quality of life of people with multiple myeloma: a cross-sectional study in Belo Horizonte, Brazil

References

• Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
   PubMed Web of Science ®Google Scholar
• Durie BGM. Mieloma Multiplo: Revisão Concisa da Doença e Opções de Tratamento São Paulo, SP: International Myeloma Foundation; 2017; [cited 2019 Dec 12]. Available from: https://www.myeloma.org.br/publicacoes.php.
   Google Scholar
• Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2018;93(8):1091–1110.
   Web of Science ®Google Scholar
• Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221–1227.
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Landgren O. A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol. 2016;43(6):682–689.
   PubMed Web of Science ®Google Scholar
• Institute for Health Metrics and Evaluation (IHME). GBD Compare. Seattle (WA): IHME, University of Washington; 2015 [cited 2021 Jul 2]. Available from: http://vizhub.healthdata.org/gbd-compare/.
   Google Scholar
• Ramsenthaler C, Osborne TR, Gao W, et al. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-Centre study. BMC Cancer. 2016;16(1):427.
   PubMed Web of Science ®Google Scholar
• Zanwar S, Abeykoon JP, Kapoor P. Challenges and strategies in the management of multiple myeloma in the elderly population. Curr Hematol Malig Rep. 2019;14(2):70–82.
   PubMed Web of Science ®Google Scholar
• Warsame R, D’Souza A. Patient reported outcomes have arrived: a practical overview for clinicians in using patient reported outcomes in oncology. Mayo Clin Proc. 2019;94(11):2291–2301.
   PubMed Web of Science ®Google Scholar
• Portaria N° 708, de 6 de agosto 2015 – Aprova as Diretrizes Diagnósticas e Terapêuticas do Mieloma Múltiplo, 2015.
   Google Scholar
• Despiegel N, Touboul C, Flinois A, et al. Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France. Clin Lymphoma Myeloma Leuk. 2019;19(1):e13–e28.
   PubMed Web of Science ®Google Scholar
• Abonour R, Rifkin RM, Gasparetto C, et al. Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry. Br J Haematol. 2021;193(1):93–100.
   PubMed Web of Science ®Google Scholar
• Acaster S, Gaugris S, Velikova G, et al. Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey. Support Care Cancer. 2013;21(2):599–607.
   PubMed Web of Science ®Google Scholar
• Maggiore RJ, Gross CP, Hurria A. Polypharmacy in older adults with cancer. Oncologist. 2010;15(5):507–522.
   PubMed Web of Science ®Google Scholar
• Nascimento R, Alvares J, Guerra AAJ, et al. Polypharmacy: a challenge for the primary health care of the brazilian unified health system. Rev Saude Publica. 2017;51(suppl 2):19s.
   PubMedGoogle Scholar
• Whitman AM, DeGregory KA, Morris AL, et al. A comprehensive look at polypharmacy and medication screening tools for the older cancer patient. Oncologist. 2016;21(6):723–730.
   PubMed Web of Science ®Google Scholar
• Umit EG, Baysal M, Bas V, et al. Polypharmacy and potentially inappropriate medication use in older patients with multiple myeloma, related to fall risk and autonomous neuropathy. J Oncol Pharm Pract. 2020;26(1):43–50.
   PubMed Web of Science ®Google Scholar
• Nunes BP, Batista SRR, Andrade FBd, et al. Multimorbidity: the brazilian longitudinal study of aging (ELSI-Brazil). Rev Saúde Pública. 2019;52(Suppl 2):10s.
   Google Scholar
• Guthrie B, Makubate B, Hernandez-Santiago V, et al. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med. 2015;13:74.
   PubMed Web of Science ®Google Scholar
• Schenker Y, Park SY, Jeong K, et al. Associations between polypharmacy, symptom burden, and quality of life in patients with advanced, life-limiting illness. J Gen Intern Med. 2019;34(4):559–566.
   PubMed Web of Science ®Google Scholar
• EORTC. EORTC Quality of life Belgium. 2019; [cited 2019 Feb 2019]. Available from: https://qol.eortc.org/modules/.
   Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376.
   PubMed Web of Science ®Google Scholar
• Cocks K, Cohen D, Wisløff F, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 2007;43(11):1670–1678.
   PubMed Web of Science ®Google Scholar
• Paiva C, Carneseca E, Barroso E, et al. Further evaluation of the EORTC QLQ-C30 psychometric properties in a large Brazilian cancer patient cohort as a function of their educational status. Support Care Cancer. 2014;22(8):2151–2160.
   PubMed Web of Science ®Google Scholar
• Etto LY, Morelli VM, Silva VC, et al. Autologous stem cell transplantation improves quality of life in economically challenged, Brazilian multiple myeloma patients. Clinics. 2011;66(11):1855–1859.
   PubMed Web of Science ®Google Scholar
• Malta JS, Silveira LP, Drummond PLM, et al. Validity and reliability of the QLQ-MY20 module for assessing the health-related quality of life in Brazilians with multiple myeloma. Curr Med Res Opin. 2021;37(7):1163–1169.
   PubMed Web of Science ®Google Scholar
• EORTC. EORTC QLQ-C30 Scoring Manual BELGIUM: EORTC Quality of Life Group; 2001; [cited 2019 Dec 17]. Available from: https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf.
   Google Scholar
• EORTC. EORTC QLQ-MY20 Scoring Manual Belgium. 2007; [cited 2020 Feb 22]. Available from: https://qol.eortc.org/manuals/.
   Google Scholar
• Ludwig H, Moreau P, Dimopoulos MA, et al. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2019;9(3):23.
   PubMed Web of Science ®Google Scholar
• Robinson D, Jr., Esseltine DL, Regnault A, et al. The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials. Br J Haematol. 2016;174(3):368–381.
   PubMed Web of Science ®Google Scholar
• Jordan K, Proskorovsky I, Lewis P, et al. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer. 2014;22(2):417–426.
   PubMed Web of Science ®Google Scholar
• van der Poel MW, Oerlemans S, Schouten HC, et al. Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry. Ann Hematol. 2015;94(4):651–661.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Verelst SG, Lewis P, et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia. 2013;27(10):1959–1969.
   PubMed Web of Science ®Google Scholar
• Naveiro-Rilo JC, Diez-Juarez D, Flores-Zurutuza ML, et al. [Quality of life in the elderly on polymedication and with multiple morbidities]. Rev Esp Geriatr Gerontol. 2014;49(4):158–164.
   PubMedGoogle Scholar
• Baz R, Lin HM, Hui AM, et al. Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life. Support Care Cancer. 2015;23(9):2789–2797.
   PubMed Web of Science ®Google Scholar
• Tegegn HG, Erku DA, Sebsibe G, et al. Medication-related quality of life among Ethiopian elderly patients with polypharmacy: a cross-sectional study in an Ethiopia university hospital. PLoS One. 2019;14(3):e0214191.
   PubMed Web of Science ®Google Scholar
• Nielsen LK, Abildgaard N, Jarden M, et al. Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma. Br J Haematol. 2019;185(1):11–24.
   PubMed Web of Science ®Google Scholar
• Aguiar PM, de Mendonca Lima T, Colleoni GWB, et al. Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with Meta-analyses. Crit Rev Oncol Hematol. 2017;113:195–212.
   PubMed Web of Science ®Google Scholar
• Weisel K, Ludwig H, Rieth A, et al. Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on german benefit assessment data. Qual Life Res. 2020;29(1):69–79.
   PubMed Web of Science ®Google Scholar
• Hungria VTM, Chiattone C, Pavlovsky M, et al. Epidemiology of hematologic malignancies in real-world settings: findings from the hemato-oncology Latin America observational registry study. J Glob Oncol. 2019;5:1–19.
   Web of Science ®Google Scholar